Key strategic choices – ‘what’ to develop
As I discussed in my last post, the key strategic issues facing biotech start-ups are capital constraint, regulatory burden and the need for complementary assets and credibility. Together, with project specific factors such as market opportunity and competition, they shape decisions about what, when, and how a firm plugs into the value chain. These decisions are captured in the firm’s business model. Over my next few posts I am going to explore the implications and trade-offs that surround each of these strategic decisions, beginning with what. Read more
Recent comments on this blog
New Trump Travel Ban a Detriment to Biotech
More on the Shelf
My Biotech Heroes